Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

A co-clinical trial of chemotherapy response in bladder cancer using patient-derived tumor organoids

Funder: V Foundation for Cancer Research

Funding period
USD 600 K
Funding amount
Abstract
The studies of this proposal will address a central question in personalized cancer treatment. Many recent studies have generated three-dimensional tissue models of human tumors, known as organoids, which can be grown and analyzed in the laboratory. Thus, these organoids can be considered “avatars” of their corresponding patient tumors. However, it is unknown whether drugs that affect organoid growth in the laboratory would have similar effects in patients. If so, patient-derived tumor organoids could be used to predict effective treatment.

We will utilize patient avatars to investigate muscle invasive bladder cancer, a highly lethal disease that is treated by chemotherapy followed by surgical removal of the bladder, which drastically affects quality of life. We will use an approach known as “co-clinical trials” to simultaneously test drug response in the clinic with that of patient avatars in the laboratory. In particular, we will determine whether patient avatars are able to predict which patients who have no residual tumor after chemotherapy can safely avoid removal of the bladder.

We have assembled an outstanding research team to investigate whether the response of patient-derived organoids to chemotherapy in the laboratory correlates with the response of the corresponding patients in the clinical trial. In addition, we will examine whether there are specific genetic alterations that are associated with sensitivity to chemotherapy. Consequently, our findings have the potential to greatly improve the standard of care for patients with muscle invasive bladder cancer.
Similar projects All >
Sorted by: Start Date
Project list item
Investigating underlying molecular mechanisms of epigenetic therapies in muscle-invasive bladder cancer

Bladder Cancer Advocacy Network to Swathi Ramakrishnan

USD 1,700
2019 - 2019
Project list item
Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer: A Mixed Methods Study of 2 Diverse Patient Populations

Bladder Cancer Advocacy Network to Sumeet Kaur Bhanvadia, Siamak Daneshmand, Reginald Tucker-Seeley

USD 50,000
2019 - 2020
Project list item
Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Bladder Cancer Advocacy Network to Sarah Psutka, Jonathan Wright, Daniel Lin, John Gore, Ryan O'Malley, Anne Browning, Florian Fintelmann

USD 50,000
2019 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020

System

Categories
  • FOR (ANZSRC)

    1103 Clinical Sciences

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • Health Research Areas

    Clinical

  • Broad Research Areas

    Clinical Medicine and Science